About BioAnalytics
BioAnalytics is a Boston-based biotechnology company that has raised $55 million in funding through a Series B round. Operating in the competitive biotech sector, the company appears to focus on analytics and data-driven solutions for the life sciences industry, though specific product details are not publicly disclosed.
The company's significant funding milestone and Series B stage suggests BioAnalytics has demonstrated market traction and is scaling its operations. Boston's position as a major biotech hub provides the company access to talent, research institutions, and industry partnerships that are crucial for biotech ventures. The substantial funding round indicates investor confidence in the company's technology platform and commercial potential.
Frequently Asked Questions
What does BioAnalytics do?
Boston-based biotech company developing analytics and data solutions for the life sciences industry.
How much funding has BioAnalytics raised?
BioAnalytics has raised $55M in total funding, with their most recent round being a Series B. The company operates in the Biotech sector.
What sector is BioAnalytics in?
BioAnalytics operates in the Biotech sector. Boston-based biotech company developing analytics and data solutions for the life sciences industry.
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Company Details
- Sector
- Biotech
- Headquarters
- Boston
- Status
- Active
- Last Funding Stage
- Series B
- Total Funding
- $55M
